<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00898677</url>
  </required_header>
  <id_info>
    <org_study_id>0462-030</org_study_id>
    <secondary_id>2009_591</secondary_id>
    <nct_id>NCT00898677</nct_id>
  </id_info>
  <brief_title>Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Examine the Safety, Tolerability, and Efficacy of Single Oral Doses of MK0462 5 mg, MK0462 10 mg, and Sumatriptan 100 mg for Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A study to compare rizatriptan 10 mg verse sumatriptan 100 mg in the treatment of migraine
      attacks and duration of relief provided. This study will also provide additional efficacy
      data on rizatriptan 5 mg and 10 mg for the treatment of migraine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 1995</start_date>
  <completion_date type="Actual">September 1996</completion_date>
  <primary_completion_date type="Actual">May 1996</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Relief at 2 Hours After Dose</measure>
    <time_frame>2 hours after dose</time_frame>
    <description>Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Relief Within 2 Hours After Dose</measure>
    <time_frame>within 2 hours after dose</time_frame>
    <description>Patients reporting time to relief defined as the first time point at which a patient reported headache severity grade 1 or 0 (mild pain or no headache) within 2 hours after dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Free at 2 Hours After Dose</measure>
    <time_frame>2 hours after dose</time_frame>
    <description>Patients pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after treatment. Each patient rated headache severity on a 4-point scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status at 2 Hours After Dose</measure>
    <time_frame>2 hours after dose</time_frame>
    <description>Patients with no functional disability measured by the level of impairment to daily activities at 2 hours after treatment. Each patient rated functional disability on a 4-grade scale (0 = no functional disability; 1 = daily activities mildly impaired; 2 = daily activities severely impaired; 3 = unable to carry out daily activities, requires bed rest).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea at 2 Hours After Dose</measure>
    <time_frame>2 hours after dose</time_frame>
    <description>Patients who recorded the presence or absence of nausea 2 hours after dose</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1268</enrollment>
  <condition>Migraine Headache</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rizatriptan 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rizatriptan 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sumatriptan 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rizatriptan benzoate</intervention_name>
    <description>single dose administration of 5mg rizatriptan (by Mouth) p.o.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>rizatriptan</other_name>
    <other_name>MK0462</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rizatriptan benzoate</intervention_name>
    <description>single dose administration of 10 mg rizatriptan p.o.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>rizatriptan</other_name>
    <other_name>MK0462</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: sumatriptan</intervention_name>
    <description>single dose administration of sumatriptan 100 p.o.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>sumatriptan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>placebo to rizatriptan</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient had at least a 6-month history of migraine, with or without aura

          -  Patient was male, or if female must have been postmenopausal, surgically sterilized,
             or taking adequate contraceptive precautions.

          -  Patient was judged to be in good health, apart from migraine

        Exclusion Criteria:

          -  Patient was pregnant or a nursing mother

          -  Patient had abused drugs or alcohol within 12 months prior to entering the study

          -  Patient had a history of cardiovascular disease

          -  Patient had clinically significant Electrocardiography (ECG) abnormality

          -  Patient had a resting systolic blood pressure of greater than 145 mm Hg or diastolic
             of less than 95 mm Hg at screening

          -  Patient received treatment with an investigational device or compound within 30 days
             of the study start

          -  Patient typically suffered from less then 1 or more than 8 attacks of migraine per
             month

          -  Patient had difficulty in distinguishing his/her migraine attacks from tension or
             interval headaches

          -  Patient had hypersensitivity to sumatriptan

          -  Patient had participated in any previous study involving rizatriptan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <reference>
    <citation>Ho TW, Rodgers A, Bigal ME. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache. 2009 Mar;49(3):395-403. doi: 10.1111/j.1526-4610.2009.01346.x. Epub 2008 Feb 12.</citation>
    <PMID>19222588</PMID>
  </reference>
  <results_reference>
    <citation>Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W, Block GA, Reines SA, Visser WH. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Headache. 1998 Nov-Dec;38(10):748-55.</citation>
    <PMID>11284463</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2009</study_first_submitted>
  <study_first_submitted_qc>May 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <results_first_submitted>May 21, 2009</results_first_submitted>
  <results_first_submitted_qc>May 22, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2009</results_first_posted>
  <last_update_submitted>February 13, 2015</last_update_submitted>
  <last_update_submitted_qc>February 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
    <mesh_term>Rizatriptan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited at 47 sites in 21 countries in Canada, South America, Europe, Middle East, South Africa, and Australia
First Patient Treated: September 1995
Last Patient Treated: May 1996</recruitment_details>
      <pre_assignment_details>Outpatients screened at a pretreatment visit were given allocated drug supply with instructions. If patients had not treated an attack within 2 months of being enrolled, they were required to return for a rescreen visit. If by 4 months after being enrolled patients still had not treated an attack, they were discontinued from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rizatriptan 5 mg</title>
          <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="P2">
          <title>Rizatriptan 10 mg</title>
          <description>Rizatriptan 10 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="P3">
          <title>Sumatriptan 100 mg</title>
          <description>Sumatriptan 100 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo matching Rizatriptan and Sumatriptan orally once for treatment of single migraine attack</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="455"/>
                <participants group_id="P3" count="455"/>
                <participants group_id="P4" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patients Treated</title>
              <participants_list>
                <participants group_id="P1" count="164">Patients Not Treated: 16</participants>
                <participants group_id="P2" count="387">Patients Not Treated: 68</participants>
                <participants group_id="P3" count="388">Patients Not Treated: 67</participants>
                <participants group_id="P4" count="160">Patients Not Treated: 18</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="386"/>
                <participants group_id="P3" count="383"/>
                <participants group_id="P4" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated: Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated: Lost to Follow-Up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated: Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated: Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated: Withdraw by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated: Patient uncooperative</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated: Abnormal Prestudy Labs</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated: Abnormal Baseline ECG</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated: No Longer Met Inc Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated: Lack of Migraine Attack</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated: Other (Not Specified)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rizatriptan 5 mg</title>
          <description>Rizatriptan 5 mg orally once for treatment of single migraine attack.
Baseline measure Participants reported are those participants that recieved study treatment.</description>
        </group>
        <group group_id="B2">
          <title>Rizatriptan 10 mg</title>
          <description>Rizatriptan 10 mg orally once for treatment of single migraine attack
Baseline measure Participants reported are those participants that recieved study treatment.</description>
        </group>
        <group group_id="B3">
          <title>Sumatriptan 100 mg</title>
          <description>Sumatriptan 100 mg orally once for treatment of single migraine attack
Baseline measure Participants reported are those participants that recieved study treatment.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo matching Rizatriptan and Sumatriptan orally once for treatment of single migraine attack
Baseline measure Participants reported are those participants that recieved study treatment.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="387"/>
            <count group_id="B3" value="388"/>
            <count group_id="B4" value="160"/>
            <count group_id="B5" value="1099"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.3" spread="10.3"/>
                    <measurement group_id="B2" value="37.0" spread="10.0"/>
                    <measurement group_id="B3" value="39.2" spread="10.1"/>
                    <measurement group_id="B4" value="38.3" spread="10.3"/>
                    <measurement group_id="B5" value="38.2" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="319"/>
                    <measurement group_id="B3" value="309"/>
                    <measurement group_id="B4" value="132"/>
                    <measurement group_id="B5" value="898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Headache Severity</title>
          <description>Each patient rated headache severity on a 4-grade scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grades 1, 0: Mild, no pain, or missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="191"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="196"/>
                    <measurement group_id="B4" value="84"/>
                    <measurement group_id="B5" value="585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="282"/>
                    <measurement group_id="B3" value="281"/>
                    <measurement group_id="B4" value="120"/>
                    <measurement group_id="B5" value="800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mestizo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexican</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexican/Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Relief at 2 Hours After Dose</title>
        <description>Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment</description>
        <time_frame>2 hours after dose</time_frame>
        <population>An “all-patients-treated” approach was used in the primary analysis, including all patients who had at least one assessment of pain severity within 2 hours after test medication. Missing values in the treatment phase (i.e., after the baseline phase) were imputed by carrying forward the preceding values in the same phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Rizatriptan 10 mg</title>
            <description>Rizatriptan 10 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Sumatriptan 100 mg</title>
            <description>Sumatriptan 100 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matching Rizatriptan and Sumatriptan orally once for treatment of single migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief at 2 Hours After Dose</title>
          <description>Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment</description>
          <population>An “all-patients-treated” approach was used in the primary analysis, including all patients who had at least one assessment of pain severity within 2 hours after test medication. Missing values in the treatment phase (i.e., after the baseline phase) were imputed by carrying forward the preceding values in the same phase.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="387"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-hour pain relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="258"/>
                    <measurement group_id="O3" value="239"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No 2-hour pain relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="127"/>
                    <measurement group_id="O3" value="148"/>
                    <measurement group_id="O4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Relief Within 2 Hours After Dose</title>
        <description>Patients reporting time to relief defined as the first time point at which a patient reported headache severity grade 1 or 0 (mild pain or no headache) within 2 hours after dose</description>
        <time_frame>within 2 hours after dose</time_frame>
        <population>An “all-patients-treated” approach was used in the primary analysis, including all patients who had at least one assessment of pain severity within 2 hours after test medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Rizatriptan 10 mg</title>
            <description>Rizatriptan 10 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Sumatriptan 100 mg</title>
            <description>Sumatriptan 100 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matching Rizatriptan and Sumatriptan orally once for treatment of single migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relief Within 2 Hours After Dose</title>
          <description>Patients reporting time to relief defined as the first time point at which a patient reported headache severity grade 1 or 0 (mild pain or no headache) within 2 hours after dose</description>
          <population>An “all-patients-treated” approach was used in the primary analysis, including all patients who had at least one assessment of pain severity within 2 hours after test medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="387"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First pain relief within 2 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="265"/>
                    <measurement group_id="O3" value="247"/>
                    <measurement group_id="O4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain relief did not occur within 2 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="140"/>
                    <measurement group_id="O4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Free at 2 Hours After Dose</title>
        <description>Patients pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after treatment. Each patient rated headache severity on a 4-point scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain).</description>
        <time_frame>2 hours after dose</time_frame>
        <population>An “all-patients-treated” approach was used in the secondary analysis, including all patients who had at least one assessment of pain severity within 2 hours after test medication. Missing values in the treatment phase (i.e., after the baseline phase) were imputed by carrying forward the preceding values in the same phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Rizatriptan 10 mg</title>
            <description>Rizatriptan 10 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Sumatriptan 100 mg</title>
            <description>Sumatriptan 100 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matching Rizatriptan and Sumatriptan orally once for treatment of single migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Free at 2 Hours After Dose</title>
          <description>Patients pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after treatment. Each patient rated headache severity on a 4-point scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain).</description>
          <population>An “all-patients-treated” approach was used in the secondary analysis, including all patients who had at least one assessment of pain severity within 2 hours after test medication. Missing values in the treatment phase (i.e., after the baseline phase) were imputed by carrying forward the preceding values in the same phase.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="387"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-hour Pain freedom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="155"/>
                    <measurement group_id="O3" value="127"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No 2-hour pain freedom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="230"/>
                    <measurement group_id="O3" value="260"/>
                    <measurement group_id="O4" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status at 2 Hours After Dose</title>
        <description>Patients with no functional disability measured by the level of impairment to daily activities at 2 hours after treatment. Each patient rated functional disability on a 4-grade scale (0 = no functional disability; 1 = daily activities mildly impaired; 2 = daily activities severely impaired; 3 = unable to carry out daily activities, requires bed rest).</description>
        <time_frame>2 hours after dose</time_frame>
        <population>An “all-patients-treated” approach was used in the secondary analysis. Missing data were replaced by carrying forward the preceding value.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Rizatriptan 10 mg</title>
            <description>Rizatriptan 10 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Sumatriptan 100 mg</title>
            <description>Sumatriptan 100 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matching Rizatriptan and Sumatriptan orally once for treatment of single migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Status at 2 Hours After Dose</title>
          <description>Patients with no functional disability measured by the level of impairment to daily activities at 2 hours after treatment. Each patient rated functional disability on a 4-grade scale (0 = no functional disability; 1 = daily activities mildly impaired; 2 = daily activities severely impaired; 3 = unable to carry out daily activities, requires bed rest).</description>
          <population>An “all-patients-treated” approach was used in the secondary analysis. Missing data were replaced by carrying forward the preceding value.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="387"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No functional disability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="160"/>
                    <measurement group_id="O3" value="126"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mildly impaired</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="123"/>
                    <measurement group_id="O3" value="142"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severely impaired</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Required bed rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea at 2 Hours After Dose</title>
        <description>Patients who recorded the presence or absence of nausea 2 hours after dose</description>
        <time_frame>2 hours after dose</time_frame>
        <population>An “all-patients-treated” approach was used in the secondary analysis. Missing data were replaced by carrying forward the preceding value.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Rizatriptan 10 mg</title>
            <description>Rizatriptan 10 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Sumatriptan 100 mg</title>
            <description>Sumatriptan 100 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matching Rizatriptan and Sumatriptan orally once for treatment of single migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea at 2 Hours After Dose</title>
          <description>Patients who recorded the presence or absence of nausea 2 hours after dose</description>
          <population>An “all-patients-treated” approach was used in the secondary analysis. Missing data were replaced by carrying forward the preceding value.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="387"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-hour Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="128"/>
                    <measurement group_id="O4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No 2-hour Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="290"/>
                    <measurement group_id="O3" value="259"/>
                    <measurement group_id="O4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the 24 hours treatment period, and up to and including 7 days after the last dose of study therapy.</time_frame>
      <desc>Although a patient may have had two or more adverse experiences the patient is counted only once in a category. The same patient may appear in different categories.
Adverse Event participants reported are those participants that received study treatment and had safety follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rizatriptan 5 mg</title>
          <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="E2">
          <title>Rizatriptan 10 mg</title>
          <description>Rizatriptan 10 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="E3">
          <title>Sumatriptan 100 mg</title>
          <description>Sumatriptan 100 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo matching Rizatriptan and Sumatriptan orally once for treatment of single migraine attack</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="159" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="188" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acid Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Perversion, Taste</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia/Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cold Sensation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pain, Abdominal</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pain, Chest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Warm Sensation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Heaviness, Regional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pain, Neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pain, Shoulder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort, Pharyngeal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="388"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

